Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Data Insights

Thumbnail
February 22, 2021

Despite Imfinzi, US accelerated approvals surge

More and more drugs are being approved conditionally on flimsy data, and Imfinzi is just the second to be pulled after failing a confirmatory trial.

Thumbnail
February 18, 2021

The reckoning begins for biotech-focused Spacs

The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.

Article image
Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

It's official: dramatic share price jumps in response to clinical data have become more common.

Article image
Vantage logo
January 20, 2021

2020 drug approvals rise despite Covid-19

Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.

Article image
Vantage logo
January 20, 2021

Focus on Covid-19 does not distract the FDA

Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.

Article image
Vantage logo
January 19, 2021

The pandemic releases its grip on clinical trials

The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.

Article image
Vantage logo
January 18, 2021

Astounding success greets newly public device makers

2020 was a bountiful year for medtechs making their public debut, with one group, Inari Medical, more than quadrupling in value.

Article image
Vantage logo
January 14, 2021

Medtechs rake in the venture cash

In terms of private investments, 2020 was the year of the liquid biopsy.

Article image
Vantage logo
January 13, 2021

After a big year, biotech flotations have much to do

Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.

Article image
Vantage logo
January 12, 2021

Medtech deal-making stands firm in difficult times

It takes more than a pandemic to stop medical device companies merging.

Vantage logo
January 11, 2021

Datapoint: the UK’s biggest biotech buyouts

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.